CINCINNATI--(BUSINESS WIRE)--Devicor® Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, announced today the acquisition of the HydroMARK® breast biopsy marker portfolio and related assets from Biopsy Sciences, LLC.
"We are proud to add HydroMARK to our existing family of Mammotome® markers," said Devicor CEO Tom Daulton. "Combining HydroMARK with our existing MammoMARK®, MammoStar® and MicroMARK® products allows us to offer customers a complete portfolio of tissue markers that meets all of their breast biopsy marking needs.”
HydroMARK was developed by Dr. John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Dr. Fisher and his team developed HydroMARK to provide physicians with a long-term ultrasound visible breast biopsy marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.
The acquisition of HydroMARK is the latest in a series of product additions by Devicor, including the addition of the Mammotome MammoTestTM stereotactic table, and a new distribution agreement with Faxitron on their CoreVision®, core specimen radiography system. These complement recent internally developed products, Mammotome revolve® and Mammotome elite®. HydroMARK is currently available in most of North and South America, Europe and parts of Asia.
“As a company, our commitment to advancing the accurate diagnosis and treatment of breast cancer has never wavered,” says Daulton. “We continue to look for technologies that complement our flagship brand, Mammotome® - the global leader in breast biopsy, as we build our innovative and market-leading organization.”
About Devicor® Medical Products, Inc.
Devicor
Medical Products, headquartered in Cincinnati, Ohio, has more than 400
employees around the world. As the global market leader, Devicor is
committed to advancing technology to help clinicians accurately diagnose
breast disease, such as breast cancer, through minimally invasive
procedures. Devicor’s product portfolio includes the world-renowned
Mammotome® Breast Biopsy System, Mammotome revolve®, the tetherless
Mammotome elite®, Neoprobe® Gamma Detection System (GDS), Mammotome
MammoTestTM stereotactic biopsy table, as well as a
comprehensive portfolio of tissue markers used in breast disease
diagnostic sampling and management. These products are sold in more than
50 countries around the world. Since its introduction in 1995, more than
4 million women have had a minimally invasive breast biopsy in
stereotactic, ultrasound or MRI-guidance imaging using the Mammotome®
Breast Biopsy System. For more information, please visit www.devicormedical.com
or www.mammotome.com.
About GTCR
Founded in 1980, GTCR is a leading private equity
firm focused on investing in growth companies in the Financial Services
& Technology, Healthcare and Information Services & Technology
industries. The Chicago-based firm pioneered The Leaders Strategy™ –
finding and partnering with management leaders in core domains to
identify, acquire and build market-leading companies through
transformational acquisitions and organic growth. Since its inception,
GTCR has invested more than $10 billion in over 200 companies. For more
information, please visit www.gtcr.com.
